Market Overview

The Ulcerative Colitis Market Size was evaluated at USD 7.2 billion in 2022 and is expected to rise from USD 7.5744 billion in 2023 to USD 10.77 billion by 2032, with a compound annual growth rate (CAGR) of 5.1% over the forecast period (2023-2032).

Growth Boosters and Deterrents

Ulcerative Colitis/UC is a debilitating disorder, affecting the large intestine or the colon. The cause is unknown but it is believed that the disease is an amplified immune response to a microbial trigger. The disease involves colon inflammation, with key symptoms including diarrhea, abdominal pain, and blood in the stool. Pfizer Inc. reveals that ulcerative colitis affects almost one million people across the United States every year. Some of the top treatment options include conventional therapies like drugs that contain tumor necrosis factor (TNF) inhibitors as well as small molecule.

Lately, the preference for minimally invasive surgeries has gone up, which will be a major trend in the worldwide market. The factors fostering the preference for minimally invasive surgeries include economic viability, better patient satisfaction, reduced hospital stay, and lower postsurgical complications.

Emerging popularity of biosimilars remains one of the top growth boosters for the ulcerative colitis industry. Biosimilars cost much less compared to biologics, raising their accessibility in developing economies. With of a few drugs’ patents about to expire, experts project launch of several new biosimilars. Additionally, the rising efforts by renowned companies with focus on product innovations should translate to substantial market growth. To illustrate, in June 2021, Pfizer Inc. started the stage III of the clinical trial reviewing the safety, pharmacokinetics (PK), and efficacy of tofacitinib for treating pediatric patients affected by active Ulcerative Colitis. The trial should be completed by October 2028. In another news, in June 2021, Takeda Pharmaceutical Company Limited (Japan), initiated the phase III of its clinical trial assessing the safety as well as efficacy of intravenous (IV) Vedolizumab in patients having moderate to severe Ulcerative Colitis. The trial should get over by September 2024.

Market Segmentation

Ulcerative colitis industry has been considered for procedures as well as medication.

With respect to procedure, the ulcerative colitis market research caters to proctosigmoiditis, ulcerative proctitis, pancolitis or universal colitis, fulminant colitis, and left-sided colitis.

Depending on medication, the worldwide market can be dissected into steroids, 5-aminosalicylates, immunomodulators, biologics, and purine analogs.

Regional Study

North America, MEA or Middle East and Africa, Europe as well as APAC or Asia Pacific are the key markets for ulcerative colitis.

North America will maintain its winning streak in the worldwide market throughout the analysis period, considering the region’s strong financial status and significantly developed healthcare system. Research institutes’ focus on technically upgradations to develop highly advanced treatment and diagnosis techniques, presence of well-equipped hospitals and the large number of skilled medical professional present in the region also add to the market’s strength. The ulcerative colitis market in the United States is extremely competitive. Many of the major firms in the country follow take a few strategic initiatives, including new product launch, merger, partnerships, and acquisition, which helps them maintain their relevance in the regional market.

Asia Pacific will be the fastest advancing market in the ensuing years, as a result of the presence of fast emerging economies like India and China that have thriving healthcare industries. Also, the accelerated cases of inflammatory bowel disease will foster the market demand during the review period. Other encouraging factors can be the advancing healthcare infrastructure combined with the rising demand for modern diagnostic therapies.

Reputed Firms

UCB S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Johnson & Johnson Services, Inc., Perrigo Company plc, Allergan, Inc., Ferring B.V., Bayer AG are the major ulcerative colitis products and solutions developers in the global industry.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com